Talaris Therapeutics, a phase 3 biotech developing methods for allogeneic hematopoietic stem cell transplantation, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Talaris Therapeutics is a late-clinical stage, cell therapy company developing methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT) that are aimed to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune, and metabolic disorders. The company's initial focus is a proprietary therapeutic approach called Facilitated Allo-HSCT Therapy that could prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines. The lead product candidate, FCR001, is a novel allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation. Patients are currently being enrolled in FREEDOM-1, a randomized, controlled, open-label Phase 3 registration trial in the US of FCR001 in 120 adult living donor kidney transplant (LDKT) recipients.
The Louisville, KY-based company was founded in 2002 and plans to list on the Nasdaq under the symbol TALS. Talaris Therapeutics filed confidentially on February 26, 2021. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
